Data investigation

Rhode Island Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals

Rhode Island Medicaid still covers Wegovy + Zepbound + Saxenda + Contrave for chronic weight management — but only until October 1, 2026: the General Assembly ENACTED the FY2027 sunset in June 2026 with no grandfathering; GLP-1 coverage is restricted to type 2 diabetes from that.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
16 min read·19 citations

Rhode Island is one of only 11 states still covering GLP-1s for weight management under Medicaid (The RX Index 50-state tracker, July 10, 2026; KFF counted 13 in January 2026) — but that coverage now has an enacted end date. The General Assembly adopted the FY2027 budget in June 2026 with Governor McKee’s GLP-1 restriction included: coverage ends October 1, 2026 with NO grandfathering or exemptions for existing patients, and GLP-1 coverage is restricted to type 2 diabetes from that date. The unusual question here — whether existing coverage would survive the legislature — has been answered: it did not. Coverage remains in effect until October 1, 2026.

Rhode Island Medicaid is administered by the Rhode Island Executive Office of Health and Human Services (EOHHS) through three programs: RIte Care (families and children), Rhody Health Partners (adults), and Integrity for Duals (dual-eligibles). Total Medicaid + CHIP enrollment is approximately 303,351 (September 2025) to 303,480 (October 2025) per healthinsurance.org citing KFF/CMS — representing roughly 28% of the state’s population of ~1.1 million, among the highest Medicaid-share-of-population rates in the United States.

Effective July 1, 2025, Rhode Island consolidated its Medicaid managed care contracts from three MCOs to two: Neighborhood Health Plan of Rhode Island (NHPRI) and UnitedHealthcare of New England (UHC). Tufts Health Plan exited managed Medicaid. Phase II (January 1, 2026) integrated fully dual-eligible beneficiaries into MCO-administered FIDE-SNPs. The state Single PDL — adopted by the EOHHS Pharmacy & Therapeutics Committee — operates as the floor across both MCO formularies.

On January 15, 2026, Governor Daniel McKee submitted his FY2027 Executive Budget. Item 028 (EOHHS Rank #2) proposed ending Rhode Island Medicaid coverage of GLP-1 receptor agonists for chronic weight management. Per Rhode Island Current’s January 27, 2026 reporting of the budget submission verbatim: "Coverage of the drugs for weight loss would end on Oct. 1 under McKee’s plan." Projected savings: $6.3 million state general revenue, $20.3 million all-funds. Cost driver per the budget verbatim: "GLP-1 weight loss costs… roughly quadrupled" between SFY 2024 start and SFY 2025 end in per-member-per-month payments to managed care plans, with projected additional growth of "approximately 130 percent (low estimate) and nearly 200 percent (high estimate) by the end of the second quarter in fiscal year 2027."

The General Assembly answered in June 2026. The House Finance Committee passed its amended $15.2 billion FY2027 budget on May 29, 2026 (11-2), and the FY2027 budget was adopted in June 2026 with the GLP-1 restriction included — outcome (a), the sunset as drafted: effective October 1, 2026, GLP-1 coverage is restricted to type 2 diabetes, with no grandfathering. Coverage remains in effect until that date. The American Diabetes Association expressed concern in a June 25, 2026 statement: "Beginning October 1, 2026, coverage for GLP-1-based medications prescribed for obesity or weight management will be eliminated."

Current coverage status (verified August 25, 2026)

What RI Medicaid covers today

  • Wegovy (semaglutide) — covered for chronic weight management with PA via NHPRI/UHC Medicaid formularies and EOHHS FFS PDL
  • Zepbound (tirzepatide) — covered for chronic weight management with PA
  • Saxenda (liraglutide) — covered for chronic weight management with PA
  • Contrave (naltrexone/bupropion) — covered for chronic weight management with PA
  • Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Bydureon BCise — covered for type 2 diabetes with PA (continues regardless of FY27 sunset)

Per KFF’s January 2026 Medicaid GLP-1 coverage tracker, Rhode Island was one of 13 states covering GLP-1s for obesity under Medicaid FFS; per The RX Index 50-state tracker (July 10, 2026) it is one of only 11 still covering — and the weight-management coverage above ends October 1, 2026 under the enacted FY2027 budget.

Confirm exact PA criteria at the source

Verbatim BMI thresholds, prerequisite lifestyle-intervention duration, prerequisite drug trials, weight-loss-milestone reauthorization thresholds, ICD-10 codes, T1D + pregnancy + MTC/MEN2 exclusions, and quantity limits should be confirmed directly from the EOHHS PDL effective January 13, 2026 (eohhs.ri.gov/sites/g/files/xkgbur226/files/2026-01/PDL%2001.13.2026.pdf) and the NHPRI Medicaid Weight Loss PA criteria PDF effective October 21, 2025 (nhpri.org/wp-content/uploads/2025/12/Medicaid_Weight_Loss_Contrave_Wegovy_Zepbound_aCAS.20251021-1.pdf). The historical RI Medicaid GLP-1 T2D PA framework requires "history of either metformin or TZD therapy in the past 90 days" as the prerequisite — the 2026 criteria should be verified against the live PDL.

The FY2027 sunset — enacted June 2026; full primary-source breakdown

Governor McKee’s FY2027 Executive Budget Item 028 (EOHHS Rank #2) was introduced January 15, 2026. The verbatim mechanism per Rhode Island Current’s reporting of the budget submission and Ocean State Media’s interview with EOHHS:

ElementDetail (verbatim where quoted)
Effective date“Coverage of the drugs for weight loss would end on Oct. 1 under McKee’s plan.” Budget document allowed flexibility: “as early as July 1, 2026, but would more likely happen by October 2026 or January 2027.” (Rhode Island Current, Jan 27, 2026.) Enacted: October 1, 2026 (FY2027 budget adopted June 2026; ADA statement June 25, 2026).
State general revenue savings$6.3 million
All-funds savings (federal + state)$20.3 million
Mechanism“Mostly an administrative change to contracts and rates” — drugs would be “struck from the preferred drug list” (EOHHS spokesperson, Ocean State Media)
Cost-growth driverPMPM payments to managed care plans “roughly quadrupled” SFY24 start → SFY25 end. Projected FY27 Q2 growth: “approximately 130 percent (low estimate) and nearly 200 percent (high estimate).”
SFY25 prescription volume24,971 prescriptions for GLP-1s addressing obesity (Becker’s Payer Issues, citing budget submission)
List-price context“$12,000 annually to roughly $16,000 annually as of March 2025” (WAC for Wegovy / Zepbound at maintenance dose)
Scope“Would only affect prescriptions for weight loss”; T2D coverage continues. “No grandfathering or exemptions for existing patients.”
Legislative pathHouse Finance Committee passed amended FY27 budget May 29, 2026 (11-2) → House and Senate passage → FY2027 budget ADOPTED June 2026 with the GLP-1 restriction included. The sunset is enacted, effective October 1, 2026; coverage restricted to type 2 diabetes from that date.
CV / OSA / MASH / pediatric carve-out languageNot publicly specified. The enacted budget item does not publicly say whether FDA-label-restricted indications (Wegovy SELECT MACE, Zepbound SURMOUNT-OSA, Wegovy ESSENCE MASH, Wegovy STEP TEENS pediatric ≥12 yrs) would be carved back in or eliminated together with the weight-loss indication. Becker’s reports EOHHS “has commented that the weight loss policy and prior authorization criteria needs to be revisited due to the updated indication for GLP-1 agonists in patients with cardiovascular disease.”

Public discourse on the proposal: the Boston Globe published a commentary on November 3, 2025 opposing the cut — “GLP-1s are a game-changer for R.I.’s obesity crisis. Limiting access to these weight-loss medications is not the answer.” Equity context per Rhode Island Current citing CDC and EOHHS data: 38.5% of Black Rhode Island residents have obesity; 33.9% of Hispanic; 29.5% of white; 44.6% of adults in households earning under $15,000. The Caseload Estimating Conference November 2025 EOHHS testimony (rilegislature.gov/Special/rcc/REC202511) contains the fiscal detail that surfaced during budget hearings. After adoption, the American Diabetes Association issued a June 25, 2026 statement expressing concern over Rhode Island’s decision: “Beginning October 1, 2026, coverage for GLP-1-based medications prescribed for obesity or weight management will be eliminated.”

PA pathway — current process (pre-sunset)

FFS submission

  • EOHHS PA Form #PA04 — Weight Management. Available at eohhs.ri.gov/providers-partners/provider-directories/pharmacy/pharmacy-prior-authorization-program. General PA form: eohhs.ri.gov/sites/g/files/xkgbur226/files/2021-03/pa_form_0.pdf
  • PA Call Center fax: 1-401-784-3889
  • Form warning verbatim: “PA FORMS LACKING ALL REQUESTED INFORMATION WILL NOT BE REVIEWED/REQUEST WILL BE DENIED.”

MCO submission

  • NHPRI: nhpri.org/providers/provider-resources/pharmacy/prior-authorization-forms/
  • UHC of New England Community Plan RI PDL (effective April 1, 2026): uhcprovider.com/content/dam/provider/docs/public/commplan/ri/pharmacy/RI-Children-SHCN-RiteCare-RhodyHealth-Preferred-Drug-List.pdf
  • For MCO denials, federal managed-care rules allow 120 calendar days to request a fair hearing after exhausting MCO internal appeal

Standard RI Medicaid PA adjudication timeframes (urgent vs standard) are not specified on the EOHHS pharmacy public pages. Federal Medicaid baseline applies: 24 hours for urgent, 14 days for standard. Any RI-specific override should be confirmed against the live EOHHS provider manual.

What Rhode Island Medicaid actually spends on GLP-1s

Rhode Island reports every Medicaid prescription and dollar it pays for each drug to CMS quarterly. In 2025, Rhode Island Medicaid paid $49M gross for GLP-1 medications across 46,691 prescriptions, with drugs labeled for weight loss (Wegovy, Zepbound, Saxenda) making up 31% of that spending. Figures are before confidential rebates — net cost is substantially lower.

QuarterWegovy rxOzempic rxAll GLP-1 gross
Q1 20251,5165,168$11M
Q2 20251,6995,698$13M
Q3 20251,7875,336$13M
Q4 20251,8975,287$13M
Q1 2026(preliminary)1,8115,147$13M

Source: CMS Medicaid State Drug Utilization Data, fee-for-service and managed care combined; quarters with small cell counts are partially suppressed by CMS, so affected figures are floors. The latest quarter fills in as Rhode Island files late reports. See the national Medicaid GLP-1 spending tracker for every state, or download the full dataset (CSV).

Appeals and fair-hearing pathway

Rhode Island Medicaid fair hearings are governed by 210-RICR-10-05-2 (Appeals Process and Procedures for EOHHS Agencies and Programs). Key verbatim provisions:

  • Filing deadline: “appeals must be filed pursuant to § 2.2.1(A)(4) of this Part within thirty (30) days of the contested agency action. The 30 days begins five (5) days after the mailing date of the notice of an intended agency action.”
  • Expedited review: available “in circumstances when the matter in dispute cannot reasonably be resolved during the standard appeals process without jeopardizing the appellant’s life, health, or ability to obtain the services required to attain, maintain, or regain maximum function.”
  • Continuation of benefits during appeal: requires filing during the “advance notice period” (10 days beginning on the fifth day after the date on the notice of intended action).
  • MCO denials (federal managed-care rules): 120 calendar days to request fair hearing — but MCO internal grievance/appeal must typically be exhausted first.
  • EOHHS Appeals Office: 3 West Road, Cranston, RI 02920. “All emergency expedited hearings will be scheduled and heard telephonically.”
  • HealthSourceRI line: (855) 840-4774. Fax: (401) 223-6317. Online filing via healthyrhode.ri.gov.
  • Forms: “EOHHS Fillable Appeal Form” and “DHS-121NF Request for Hearing”
  • Legal representation: Rhode Island Legal Services, (401) 274-2652 or (800) 662-5034 — free representation for Medicaid appeals.

Primary sources: 210-RICR-10-05-2 · EOHHS Appeals Office · File an Appeal

What Rhode Island beneficiaries should do right now

The General Assembly adopted the FY2027 budget in June 2026 with the GLP-1 sunset included — leaving the weeks remaining before the October 1, 2026 effective date for affected patients to plan. Five practical actions:

  1. Document indication-eligible diagnoses NOW. Whether or not indication-restricted carve-outs are preserved after the sunset, having a documented qualifying indication on file is your most durable path to continued access. Engage your prescriber to confirm and document: established cardiovascular disease (prior MI, stroke, symptomatic peripheral arterial disease), moderate-to-severe OSA (AHI ≥ 15 from sleep study within the last 24-36 months with documented CPAP failure or intolerance for 90+ days), biopsy-proven MASH F2-F3 fibrosis (if applicable), or T2D (if applicable). Restructure your PA on file around the FDA-label-restricted indication, not chronic weight management.
  2. Engage your prescriber about contingency planning. Discuss cash-pay manufacturer options (NovoCare Wegovy $199-$349/month, LillyDirect Zepbound vials $299-$699/month, LillyDirect Foundayo $149/month), patient assistance programs (Novo Nordisk PAP, Lilly Cares), and the timing of any planned dose changes that might trigger re-PA close to the sunset window. Our cheapest semaglutide providers guide and GLP-1 pricing index compare those cash-pay routes side by side.
  3. Request a 90-day supply at last-covered approval if you are at the maintenance dose. If you are stable on Wegovy 1.7-2.4 mg, Zepbound 7.5-15 mg, or Saxenda 3.0 mg and the FY27 sunset takes effect mid-titration, a 90-day supply approved before October 1 provides bridge coverage through January 2027.
  4. File for fair hearing within 30 days of any denial. Request expedited review if the matter cannot reasonably wait. Free representation is available through Rhode Island Legal Services (401-274-2652 or 800-662-5034).
  5. Weigh in for future sessions. The FY2027 budget is enacted, but coverage policy can change in later sessions — contact your state senator and representative through rilegislature.gov if continued coverage matters to you. The Boston Globe’s November 2025 commentary and the American Diabetes Association’s June 25, 2026 statement are part of that continuing public-discourse arc.

Where Rhode Island fits among state Medicaid programs

Rhode Island is structurally distinct from most state programs. Across the state Medicaid programs we’ve reviewed, three coverage-architecture types emerge:

GroupStatesPolicy question
Categorical exclusion + carve-back-in (Wegovy CV / OSA / MASH / pediatric)ME, WV, AR, OK, UT, NE, MSIs there a carve-back-in pathway? Document CV/OSA/MASH indication to ACCESS otherwise-excluded coverage.
Active-coverage stable (no public sunset proposal)CT, NY, WI, MIStandard PA management; coverage in place, no immediate sunset risk.
Active-coverage with ENACTED sunsetRhode Island (sunset enacted June 2026, effective October 1, 2026)Coverage did NOT survive the legislature. Document CV/OSA/MASH/T2D-comorbid indication BEFORE Oct 1, 2026 — coverage is restricted to T2D from that date.
Coverage previously droppedCA, NH, PA, SC, MA (Jul 1, 2026), UT (pilot expired Jun 30, 2026), NC (briefly)Coverage eliminated; cash-pay or compounded telehealth only (indication carve-outs vary by state).

The reader-action framing here is the inverse of the categorical-exclusion peer cluster. Where Maine readers ask “can I access GLP-1 coverage by qualifying for the Wegovy CV or Zepbound OSA carve-out?”, Rhode Island readers ask “can I preserve my existing GLP-1 coverage past October 1, 2026 by ensuring my qualifying indication is on file?”

Massachusetts’s parallel MassHealth sunset executed July 1, 2026, and Utah’s legislative pilot expired June 30, 2026 — Rhode Island’s enacted October 1, 2026 sunset makes it the next domino to fall in the trajectory that California, New Hampshire, Pennsylvania, and South Carolina began. Affected beneficiaries should treat Rhode Island as a leading indicator of what may unfold in the remaining active-coverage states facing similar PMPM-quadruple cost pressure.

Related coverage

  • Hawaii Med-QUEST GLP-1 Coverage — mirror image of RI on political-direction axis: HI currently EXCLUDES Wegovy/Zepbound/Saxenda/Contrave for weight management (AlohaCare verbatim: “Drugs for weight loss, erectile dysfunction, infertility, and cosmetic purposes are not covered”) but SB 3195 (Sen. Kurt Fevella R-Ewa Beach, bipartisan, 2026 Regular Session) would scrap the exclusion entirely AND prohibit PA; RI’s Democratic-governor-proposed sunset of existing coverage was enacted June 2026 (effective October 1, 2026). HI operates one of the longest-running continuous 1115 demonstrations (since August 1, 1994; extended through Dec 31, 2029).
  • Alaska Medicaid GLP-1 Coverage — opposite coverage posture to RI: AK Medicaid PDL effective March 1, 2026 lists Ozempic / Mounjaro / Rybelsus / Trulicity / Victoza / Bydureon BCISE / Adlyxin as preferred “ON” status but Wegovy / Zepbound / Saxenda do NOT appear in any class of the 42-page PDL (exclusion-by-absence in a Medicaid-expansion state). FFS-only with no MCOs; 231,000+ Medicaid/CHIP enrollees on a single statewide PDL; 229+ federally recognized tribes with Alaska Area IHS + ANTHC operating 8 tribally managed hospitals + 72 tribal health centers + 148 village clinics; 100% FMAP for AI/AN beneficiaries; expansion via Gov. Walker executive action September 1, 2015; PBM Prime Therapeutics Medicaid Administration; single General PA Form for ALL non-preferred drugs; appeals 30 days under 7 AAC 49.030 to Gainwell Fair Hearings
  • Wyoming Medicaid GLP-1 Coverage — inverse coverage trajectory to RI: WY codifies a categorical “Anorexiant products” exclusion in the WDH Pharmacy Services Manual Revision 27 (effective April 15, 2026) page 8 with three FDA-label carve-ins (Wegovy SELECT/CV, Wegovy MASH, Zepbound OSA — the LEAST restrictive OSA carve-in in the categorical cohort, with no CPAP prerequisite); FFS-only with no traditional MCO, WYhealth as Care Management Entity; OptumRx as pharmacy benefit administrator (load-bearing 2026 migration eff. April 15, 2026); smallest US state by population (~580K, ~59,714 enrollment per CMS Oct 2025); non-expansion (2026 expansion defeated 7-23 and 5-26); no AOM legislation 2024-2026; state-employee EGI plan launched GLP-1 weight management via CVS Caremark January 1, 2026
  • Montana Medicaid GLP-1 Coverage — categorical weight-loss exclusion under DPHHS / Mountain-Pacific Quality Health PA after HB 245 made expansion permanent (first state to convert sunsetting expansion to non-sunsetting) and SB 417 (Sen. Ellie Boldman AOM mandate) died 11-1 in committee March 1, 2025; PCCM (Passport to Health) architecture, not capitated MCO
  • North Dakota Medicaid GLP-1 Coverage — middle-ground “covered for everything except obesity”: ND covers Wegovy MACE + Wegovy MASH + Zepbound OSA (one of the most restrictive OSA carve-outs) + Ozempic/Victoza no-PA for antipsychotic-induced weight gain + Imcivree + low-cost AOMs without PA but NOT Wegovy/Zepbound/Saxenda for standalone obesity; HB 1451 / HB 1452 FAILED 12-81 / 11-82 on House floor 02/12/2025; ND 2025 commercial EHB covers GLP-1s for morbid obesity (inverse of Medicaid)
  • South Dakota Medicaid GLP-1 Coverage — opposite trajectory to RI: SD operates a functional AOM exclusion by ABSENCE (no codified categorical language; the OptumRx SD-specific GLP-1 PA form pre-codes ONLY T2D as the indication checkbox) under FFS-only DSS architecture; ballot-initiative expansion via Amendment D 2022 plus uniquely constitutionalized 90% FMAP trigger on the Nov 3, 2026 ballot via Constitutional Amendment I (HJR 5001 referred House 59-7 / Senate 31-3)
  • Idaho Medicaid GLP-1 Coverage — inverse-trajectory comparison to RI: where RI covers baseline AOM only until the enacted October 1, 2026 sunset, ID excludes baseline AOM through an OPERATIONAL (not statutory) exclusion — IDAPA 16.03.09.662 does NOT enumerate anti-obesity drugs as an excluded class (lower bar to administrative carve-back-in than statutory states); active legislative repeal trajectory (HB 138 defeated 2025, HB 345 signed MCO-by-2030, HB 913 signed April 11, 2026 work-requirements-by-2027) + Office of Group Insurance dropped GLP-1 obesity coverage Nov 1, 2025 create political compounding; PBM Prime Therapeutics; 24-hour PA adjudication; appeals 28 days to neutral / independent OAH
  • Kansas Medicaid GLP-1 Coverage — inverse trajectory: positive-coverage non-expansion state that LOOSENED AOM criteria 2024-2025 by de-listing Wegovy + Zepbound from Table 4 (BMI ≥ 40 severe-obesity gate eliminated) during the same window RI enacted the ELIMINATION of coverage entirely (effective October 1, 2026); the only state in the KFF January 2026 13-state active-coverage cohort whose policy direction was unambiguously LOOSENING
  • Delaware Medicaid GLP-1 Coverage — positive-coverage stable state with unified DMAP PDL across 3 MCOs (Wegovy + Saxenda preferred; Zepbound clinical-exception pathway); §1115 Diamond State Health Plan extended through December 31, 2028; distinct from SEBC state-employee plan $200 copay effective July 1, 2026
  • Vermont Medicaid GLP-1 Coverage — adjacent New England state with the inverse posture: VT excludes baseline AOM but operationalizes three FDA-label carve-outs (Wegovy MACE + Wegovy MASH + Zepbound OSA) under FFS-only Optum-administered pharmacy benefit
  • Maine MaineCare GLP-1 Coverage — categorical exclusion with NO Wegovy MASH carve-out; LD 480 killed March 20, 2025
  • Nebraska Medicaid GLP-1 Coverage — categorical exclusion with 45-74 age gate + 6-month MASH prerequisite; LB907 Indefinitely Postponed
  • Utah Medicaid GLP-1 Coverage — weight-loss legislative pilot expired 6/30/2026 without renewal; MACE/OSA/MASH carve-outs continue (strictest OSA criteria: in-lab attended PSG + 70% PAP adherence)
  • West Virginia Medicaid GLP-1 Coverage — categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs
  • Mississippi Medicaid GLP-1 Coverage — only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages-12+ pathway
  • 50-state Medicaid GLP-1 coverage map — full state-by-state overview
  • GLP-1 insurance coverage hub — Medicare, Medicaid, and commercial coverage landscape
  • GLP-1 insurance dropped coverage appeal playbook — denial-recovery patterns applicable across states

Primary sources

  1. RI Medicaid Preferred Drug List effective January 13, 2026 — EOHHS FFS
  2. RI EOHHS Pharmacy Program landing
  3. RI EOHHS Pharmacy PA Program (PA forms hub)
  4. 210-RICR-10-05-2 Appeals Process and Procedures — Rhode Island Code of Regulations
  5. Rhode Island Current — McKee’s FY2027 budget drops GLP-1 for weight loss (January 27, 2026)
  6. EOHHS FY2027 Operating Budget Submission, Item 028
  7. Ocean State Media — McKee’s FY2027 budget drops GLP-1 drugs
  8. Becker’s Payer Issues — RI eyes sunset for GLP-1 Medicaid weight-loss coverage
  9. NHPRI Medicaid Weight-Loss PA criteria (Wegovy / Zepbound / Contrave / Saxenda) — effective October 21, 2025
  10. NHPRI Medicaid GLP-1 / GIP-GLP-1 Agonist PA criteria — effective March 17, 2026
  11. UHC Community Plan RI PDL — effective April 1, 2026
  12. Governor McKee FY2027 Budget Press Release
  13. Governor McKee MCO Procurement Announcement (NHPRI + UHC)
  14. KFF — Medicaid Coverage of and Spending on GLP-1s
  15. healthinsurance.org — Rhode Island Medicaid eligibility and enrollment
  16. Boston Globe commentary — GLP-1s game-changer for RI obesity (November 3, 2025)
  17. Stateline — More states consider dropping GLP-1 (April 30, 2026)
  18. American Diabetes Association — press release expressing concern over Rhode Island’s decision (June 25, 2026) — confirms the enacted sunset: “Beginning October 1, 2026, coverage for GLP-1-based medications prescribed for obesity or weight management will be eliminated.” Accessed August 25, 2026
  19. Rhode Island Current — The case for maintaining Medicaid coverage for GLP-1s to treat obesity in Rhode Island (June 10, 2026) — accessed August 25, 2026

This article is a primary-source compendium for Rhode Island Medicaid GLP-1 coverage, first verified May 15, 2026 and re-verified August 25, 2026 following the June 2026 adoption of the FY2027 budget. It is informational and educational; it is not medical or legal advice. The October 1, 2026 sunset is enacted; EOHHS PDL revisions will implement it. For your individual coverage and PA decisions, consult your prescriber, your Medicaid plan, and the EOHHS Appeals Office.

Further reading

Frequently Asked Questions

Yes, but only until October 1, 2026. Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Contrave (naltrexone/bupropion) are still covered with prior authorization under the EOHHS PDL effective January 13, 2026, and via Neighborhood Health Plan of Rhode Island (NHPRI) and UnitedHealthcare of New England (UHC) Medicaid formularies — Rhode Island is one of only 11 states still covering GLP-1s for weight management per The RX Index 50-state tracker (July 10, 2026). However, the General Assembly ADOPTED the FY2027 budget in June 2026 with Governor McKee's GLP-1 restriction included: the sunset is now ENACTED, not proposed. Effective October 1, 2026, GLP-1 coverage is restricted to type 2 diabetes, with NO grandfathering or exemptions for existing patients. Per the American Diabetes Association's June 25, 2026 statement: 'Beginning October 1, 2026, coverage for GLP-1-based medications prescribed for obesity or weight management will be eliminated.' Rhode Island beneficiaries currently on a GLP-1 for weight loss should engage with their prescriber NOW about contingency planning, including documentation of any qualifying cardiovascular, sleep apnea, or T2D indication that may bear on post-sunset access.
Governor Daniel McKee's FY2027 Executive Budget — introduced January 15, 2026 — included Item 028 (EOHHS Rank #2) proposing to strike GLP-1 weight-loss drugs from the Rhode Island Medicaid Preferred Drug List. The General Assembly adopted the FY2027 budget in June 2026 with the restriction included, so the sunset is now enacted, effective October 1, 2026. Effective date per the budget submission: 'as early as July 1, 2026, but would more likely happen by October 2026 or January 2027' — with Rhode Island Current reporting 'Coverage of the drugs for weight loss would end on Oct. 1 under McKee's plan.' Projected savings: $6.3 million state general revenue, $20.3 million all-funds (federal + state combined). Mechanism per EOHHS: 'mostly an administrative change to contracts and rates' — the drugs would be 'struck from the preferred drug list.' Scope: 'would only affect prescriptions for weight loss' (T2D coverage continues); 'no grandfathering or exemptions for existing patients.' Cost driver per the budget: GLP-1 weight-loss PMPM payments to managed care plans 'roughly quadrupled' between SFY24 start and SFY25 end, with projected additional growth of approximately 130 percent (low estimate) to nearly 200 percent (high estimate) by end of FY27 Q2.
Per Rhode Island Current's reporting of the EOHHS FY2027 budget submission, Rhode Island Medicaid paid for 24,971 GLP-1 weight-loss prescriptions in State Fiscal Year 2025 (July 1, 2024 — June 30, 2025). The number of unique beneficiaries is not publicly broken out but, assuming average refill cadence, represents several thousand unique patients who face therapy discontinuation when the enacted FY27 sunset takes effect October 1, 2026 without grandfathering. Equity context per RI Current citing CDC and EOHHS data: 38.5% of Black Rhode Island residents have obesity; 33.9% of Hispanic residents; 29.5% of white residents; 44.6% of adults in households earning under $15,000. Total Rhode Island Medicaid + CHIP enrollment is approximately 303,351 (September 2025) to 303,480 (October 2025) per healthinsurance.org citing KFF/CMS, with 76,455 ACA expansion enrollees as of June 2025. List price context per the budget submission: Wegovy and Zepbound run '$12,000 annually to roughly $16,000 annually as of March 2025' at WAC.
Yes. Governor's executive budget proposals are not self-executing — they must pass the General Assembly — and this one did: the House Finance Committee passed its amended $15.2 billion FY2027 budget on May 29, 2026 (11-2 vote), and the General Assembly adopted the FY2027 budget in June 2026 with the GLP-1 restriction included. Of the three possible outcomes — accept as drafted, accept with modifications (grandfathering or carve-outs), or reject — the legislature accepted the sunset as drafted: coverage of GLP-1s prescribed for obesity or weight management ends October 1, 2026, with no grandfathering; GLP-1 coverage is restricted to type 2 diabetes from that date. The American Diabetes Association issued a June 25, 2026 statement expressing concern over the decision: 'Beginning October 1, 2026, coverage for GLP-1-based medications prescribed for obesity or weight management will be eliminated.' The Boston Globe had published a November 3, 2025 commentary opposing the cut: 'GLP-1s are a game-changer for R.I.’s obesity crisis. Limiting access to these weight-loss medications is not the answer.'
This is not yet publicly resolved, and it is the most consequential ambiguity in the now-enacted FY27 sunset. The adopted budget restricts GLP-1 coverage to type 2 diabetes beginning October 1, 2026, and does NOT publicly specify whether FDA-label-restricted indications (Wegovy for major adverse cardiovascular event risk reduction per the SELECT trial, Zepbound for moderate-to-severe obstructive sleep apnea per SURMOUNT-OSA, Wegovy for MASH per the ESSENCE trial, Wegovy pediatric ≥12 yrs per STEP TEENS) would be carved back in or eliminated together with the weight-loss indication. Becker's Payer Issues reported that EOHHS 'has commented that the weight loss policy and prior authorization criteria needs to be revisited due to the updated indication for GLP-1 agonists in patients with cardiovascular disease,' suggesting the carve-out framing is under active discussion but no public document confirms intent. PRACTICAL READER ACTION: Rhode Island beneficiaries who have established cardiovascular disease (prior MI, stroke, symptomatic PAD), moderate-to-severe OSA (AHI ≥ 15 with CPAP failure/intolerance), biopsy-proven MASH F2-F3 fibrosis, or T2D should ensure these diagnoses are documented in the medical record AND on the PA before October 1, 2026 — because if EOHHS preserves indication-restricted carve-outs after the sunset, prior documentation will be the gating factor for continued access.
Yes. The enacted FY2027 sunset is explicitly scoped to weight-loss-indicated GLP-1 prescriptions only. T2D-indicated GLP-1 receptor agonists — Ozempic (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), Victoza (liraglutide), Rybelsus (oral semaglutide), and Bydureon BCise (exenatide ER) — continue to be covered under the existing RI Medicaid GLP-1 PA criteria for type 2 diabetes. The historical RI Medicaid PA framework requires 'history of either metformin or TZD therapy in the past 90 days' as the prerequisite for both the GLP-1 receptor agonist class and the DPP-IV inhibitor class. The specific 2026 PA criteria — A1c thresholds, step therapy sequencing, quantity limits, preferred-vs-non-preferred status by brand — should be verified directly from the EOHHS PDL effective January 13, 2026 (URL: eohhs.ri.gov/sites/g/files/xkgbur226/files/2026-01/PDL%2001.13.2026.pdf) and the NHPRI Medicaid GLP-1 Agonists / GIP-GLP-1 Agonists PA criteria PDF effective March 17, 2026.
Until the enacted FY2027 sunset takes effect October 1, 2026, prior authorization for chronic-weight-management drugs operates through the EOHHS FFS PDL or, for MCO-enrolled beneficiaries, through Neighborhood Health Plan of Rhode Island (NHPRI) or UnitedHealthcare of New England (UHC) Medicaid PA pathways. PA Form #PA04 (Weight Management) is the EOHHS form, available at eohhs.ri.gov/providers-partners/provider-directories/pharmacy/pharmacy-prior-authorization-program. PA Call Center fax: 1-401-784-3889. The EOHHS pharmacy PA program publishes the verbatim warning: 'PA FORMS LACKING ALL REQUESTED INFORMATION WILL NOT BE REVIEWED/REQUEST WILL BE DENIED.' NHPRI publishes its 2026 Medicaid Weight Loss PA criteria (Wegovy, Zepbound, Contrave, Saxenda) at nhpri.org/wp-content/uploads/2025/12/Medicaid_Weight_Loss_Contrave_Wegovy_Zepbound_aCAS.20251021-1.pdf (effective October 21, 2025). Verbatim criteria — BMI thresholds, prerequisite lifestyle intervention duration, prerequisite drug trials, weight-loss-milestone reauthorization thresholds, ICD-10 codes, T1D + pregnancy + MTC/MEN2 exclusions, quantity limits — should be confirmed directly from that PDF; open it in a browser for the exact wording.
Effective July 1, 2025, Rhode Island consolidated its Medicaid managed care contracts from three MCOs to two: Neighborhood Health Plan of Rhode Island (NHPRI) and UnitedHealthcare of New England (UHC). Tufts Health Plan exited managed Medicaid. Phase II of the procurement (January 1, 2026) moved fully dual-eligible beneficiaries into MCO-administered Fully Integrated Dual Eligible Special Needs Plans (FIDE-SNPs). The state Single PDL — adopted by the EOHHS Pharmacy & Therapeutics Committee — operates as the floor across both MCO formularies; MCOs may add brand-specific preferences but cannot deny coverage of PDL-preferred therapies. RI Medicaid programs by population: RIte Care (families and children); Rhody Health Partners (adults); Integrity for Duals (dual-eligibles). The EOHHS P&T Committee meets in person at the RI EOHHS Virks Building in Cranston (see the EOHHS pharmacy page for the current meeting schedule). Total Medicaid + CHIP enrollment: approximately 303,000 (~28% of Rhode Island's population of ~1.1 million — among the highest Medicaid penetration rates by share of population in the United States).
Rhode Island Medicaid fair hearings are governed by 210-RICR-10-05-2 (Appeals Process and Procedures for EOHHS Agencies and Programs). Verbatim from the regulation: 'appeals must be filed pursuant to § 2.2.1(A)(4) of this Part within thirty (30) days of the contested agency action. The 30 days begins five (5) days after the mailing date of the notice of an intended agency action.' Expedited review is available 'in circumstances when the matter in dispute cannot reasonably be resolved during the standard appeals process without jeopardizing the appellant's life, health, or ability to obtain the services required to attain, maintain, or regain maximum function.' Continuation of benefits during appeal requires filing during the 'advance notice period' (10 days beginning on the fifth day after the date on the notice of intended action). For MCO denials, federal managed-care rules separately allow beneficiaries 120 calendar days to request a fair hearing — but the MCO internal grievance/appeal must typically be exhausted before fair hearing for non-eligibility disputes (PA denials = MCO appeal first). Contacts: EOHHS Appeals Office, 3 West Road, Cranston, RI 02920; HealthSourceRI line (855) 840-4774; fax (401) 223-6317; online filing via healthyrhode.ri.gov. Legal representation: Rhode Island Legal Services (401) 274-2652 or (800) 662-5034. 'All emergency expedited hearings will be scheduled and heard telephonically' per the EOHHS Appeals Office page.
Rhode Island is structurally distinct from most state programs. Maine, West Virginia, Arkansas, Oklahoma, Utah, and Nebraska are CATEGORICAL-EXCLUSION states — long-standing AOM exclusions under federal Medicaid §1927(d)(2)(A) where the policy question is 'is there a carve-back-in pathway?' Rhode Island faces the INVERSE question: 'will existing coverage survive the legislature?' RI's Medicaid GLP-1 weight-loss PMPM grew approximately 400% in 18 months (SFY24 start through SFY25 end), creating fiscal pressure that drove California, New Hampshire, Pennsylvania, and South Carolina to drop coverage. Massachusetts's parallel MassHealth sunset executed July 1, 2026, and Rhode Island's own answer arrived in June 2026: the General Assembly enacted the sunset, effective October 1, 2026, without grandfathering. The reader-action framing is therefore inverse: instead of 'document your CV/OSA/MASH indication to access otherwise-excluded coverage' (the Maine, WV, AR, OK, UT, NE approach), RI patients should 'document any qualifying CV/OSA/MASH/T2D-comorbid indication BEFORE October 1, 2026' — the enacted restriction limits coverage to type 2 diabetes from that date, and documentation on file is the gating factor if indication carve-outs are preserved. Mississippi — the only non-expansion southern positive-coverage state — operates yet a third model via SPA 23-0013 carve-back-in with explicit pediatric ages-12+ pathway and a CDC growth-chart BMI-percentile table in the PA form.
Yes. Rhode Island expanded Medicaid under the Affordable Care Act effective January 1, 2014 — the same effective date as the federal expansion start — extending coverage to adults 19-64 at or below 138% of the federal poverty level. Total Rhode Island Medicaid + CHIP enrollment is approximately 303,351 (September 2025) per healthinsurance.org citing KFF/CMS, representing roughly 28% of Rhode Island's population of approximately 1.1 million — among the highest Medicaid-share-of-population rates in the United States. ACA expansion enrollees specifically: 76,455 as of June 2025. Rhode Island has historically been one of the most progressive states on Medicaid coverage of anti-obesity medications, having maintained AOM coverage when many state Medicaid programs declined to extend it. The McKee FY2027 sunset — enacted by the General Assembly in June 2026, effective October 1, 2026 — represents a policy reversal of Rhode Island's prior progressive AOM stance, joining the trajectory of California, New Hampshire, Pennsylvania, and South Carolina.
The enacted FY2027 sunset takes effect October 1, 2026 without grandfathering, and affected Rhode Island beneficiaries have several practical paths. (1) Manufacturer cash-pay: Novo Nordisk NovoCare Wegovy at $199-$349/month depending on dose and pen vs. oral; LillyDirect Zepbound vials at $299-$699/month; LillyDirect Foundayo (orforglipron, FDA-approved April 1, 2026) at $149/month self-pay. (2) Patient assistance programs: Novo Nordisk PAP for Wegovy and Lilly Cares for Zepbound, both income-tested. (3) LegitScript-approved compounded telehealth: typical market prices $99-$199/month for compounded semaglutide and $149-$249/month for compounded tirzepatide as of May 2026 — but note the FDA tirzepatide compounding-resolved status (October 2024) and semaglutide compounding-resolved status (February 2025) means new compounded prescriptions require documented patient-specific clinical need beyond shortage justification. (4) Indication-specific appeal: if EOHHS preserves CV/OSA/MASH/T2D-comorbid indication carve-outs after the sunset, beneficiaries with established CVD, moderate-to-severe OSA, biopsy-proven MASH F2-F3, or T2D should file a fresh PA citing the FDA-labeled indication rather than weight loss. (5) Employer-sponsored insurance: Rhode Island beneficiaries who transition off Medicaid (e.g., expansion population at 138% FPL who increase earnings) should investigate ESI formulary options.
No standalone bill in the Rhode Island General Assembly 2025 or 2026 sessions specifically addressed GLP-1 or AOM Medicaid coverage. The policy lever was the FY2027 Executive Budget itself (Item 028, EOHHS Rank #2), which the General Assembly adopted in June 2026 with the GLP-1 restriction included — the sunset is enacted, effective October 1, 2026. The House Finance Committee and Senate Finance Committee were the operative venues. Rhode Island General Assembly tracker: rilegislature.gov. Caseload Estimating Conference November 2025 EOHHS testimony (rilegislature.gov/Special/rcc/REC202511) contains the underlying fiscal detail. The Boston Globe published a November 3, 2025 commentary opposing the cut, and the American Diabetes Association expressed concern in a June 25, 2026 statement after adoption — but the restriction passed as drafted.
Five practical actions before the enacted October 1, 2026 sunset takes effect. (1) Document indication-eligible diagnoses in your medical record: cardiovascular disease history (MI, stroke, symptomatic PAD), moderate-to-severe OSA (AHI ≥ 15 from a sleep study with documented CPAP failure or intolerance for 90+ days), biopsy-proven MASH F2-F3 fibrosis (if applicable), or T2D (if applicable). If any of these are present, ensure your PA on file is structured around the indication-restricted carve-out language, not chronic weight management — because if indication carve-outs are preserved after the sunset, the diagnosis on file will gate continued access. (2) Engage your prescriber NOW about contingency planning — including the cash-pay manufacturer options (NovoCare Wegovy, LillyDirect Zepbound, LillyDirect Foundayo) and timing of any planned dose changes that might trigger re-PA. (3) If you are at the maintenance dose threshold (e.g., Wegovy 1.7-2.4 mg, Zepbound 7.5-15 mg, Saxenda 3.0 mg) and the FY27 sunset takes effect mid-titration, request a 90-day supply at last-covered approval. (4) File for fair hearing within 30 days of any denial — and request expedited review if the matter cannot reasonably wait. (5) The FY2027 budget is enacted, but coverage policy can change in future sessions — contact your state senator and representative through rilegislature.gov if continued coverage matters to you. Rhode Island Legal Services (401-274-2652 or 800-662-5034) provides free representation for Medicaid appeals.
No. Like every other state Medicaid program, Rhode Island Medicaid does not reimburse compounded semaglutide or compounded tirzepatide under any pathway. The PDL covers specific FDA-approved branded products (Wegovy, Zepbound, Saxenda, Contrave for weight management; Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Bydureon BCise for T2D); compounded versions fall outside the FDA-approved labeling that gates PDL coverage. Rhode Island patients who use compounded GLP-1 products pay out-of-pocket through LegitScript-approved telehealth platforms. The October 2024 FDA tirzepatide compounding-resolved declaration and February 2025 semaglutide compounding-resolved declaration mean new compounded prescriptions for these molecules now require documented patient-specific clinical need beyond the previous shortage justification. Note that when RI Medicaid drops branded GLP-1 weight-loss coverage on October 1, 2026, the compounded option becomes the only sub-$300/month path for affected patients — but the FDA's resolved-shortage framework constrains the legality of new compounded prescriptions for unmodified molecules.